HWP
VRTX icon

Hibernia Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Hibernia Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$695 – 328
2023
Q3 		$695 Buy
+2
New +$699 ﹤0.01% 305

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Hibernia Wealth Partners's VRTX Position: Q4 2023 in Review

Hibernia Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 2 shares — an estimated $695 sold.

Hibernia Wealth Partners first reported a position in VRTX in Q3 2023 and held it in 1 quarter. The position peaked at $695 in Q3 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Hibernia Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Hibernia Wealth Partners sold 2 Vertex Pharmaceuticals shares in Q4 2023, an estimated $695.
  • Hibernia Wealth Partners first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Hibernia Wealth Partners's Vertex Pharmaceuticals position peaked at $695 in Q3 2023.
  • 1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Hibernia Wealth Partners's 13F filing for Q4 2023, filed 19 Jan 2024.